


## PHARMACEUTICAL 2021



## Aurinia Pharmaceuticals Inc. Rank 107 of 409





## PHARMACEUTICAL 2021



## Aurinia Pharmaceuticals Inc. Rank 107 of 409

The relative strengths and weaknesses of Aurinia Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aurinia Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Aurinia Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 12%, being 367% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	419,427
Cost of Goods Sold	0
Intangible Assets	9,332
Liabilities, Current	31,997
Liabilities, Non-Current	9,208
Other Assets	30,116
Other Compr. Net Income	0
Other Expenses	8,004
Other Liabilities	14,706
Other Net Income	1,516
Property and Equipment	4,786
Research and Development	50,327
Revenues	50,118
Selling, General and Administrative Expense	95,983

Output Variable	Value in 1000 USD
Assets	463,661
Liabilities	55,911
Expenses	154,314
Stockholders Equity	407,750
Net Income	-102,680
Comprehensive Net Income	-102,680
Economic Capital Ratio	12%